NASDAQ · FDMT
Healthcare · Biotechnology
$12.92
Down-$0.36 (-2.79%)
Updated Oct 7, 2026, 12:13 AM
SID Score
5.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · FDMT
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
FDMT closed at $12.92 after 20 trading sessions, down 11.69% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $13.86 | $13.86 | $12.61 | $12.92 | 2.11M |
| Oct 2, 2026 | $14.12 | $14.135 | $13.60 | $13.67 | 1.04M |
| Oct 1, 2026 | $14.23 | $14.58 | $13.80 | $13.84 | 655.46K |
| Sep 30, 2026 | $14.76 | $14.83 | $14.075 | $14.31 | 1.04M |
| Sep 29, 2026 | $14.70 | $14.97 | $13.935 | $14.49 | 1.38M |
| Sep 28, 2026 | $14.355 | $14.82 | $13.92 | $14.56 | 1.56M |
| Sep 25, 2026 | $14.775 | $14.82 | $14.03 | $14.47 | 1.02M |
| Sep 24, 2026 | $14.81 | $14.9799 | $13.56 | $14.71 | 1.77M |
| Sep 23, 2026 | $15.97 | $15.97 | $14.68 | $15.00 | 1.47M |
| Sep 22, 2026 | $15.21 | $16.23 | $15.13 | $15.88 | 936.97K |
| Sep 21, 2026 | $15.57 | $15.70 | $14.681 | $15.24 | 699.18K |
| Sep 18, 2026 | $15.12 | $15.69 | $14.7826 | $15.22 | 1.79M |
| Sep 17, 2026 | $13.93 | $14.87 | $13.93 | $14.68 | 930.58K |
| Sep 16, 2026 | $13.65 | $14.1999 | $13.545 | $13.76 | 819.58K |
| Sep 15, 2026 | $13.95 | $13.95 | $13.18 | $13.63 | 552.04K |
| Sep 14, 2026 | $13.64 | $14.185 | $13.43 | $13.76 | 977.25K |
| Sep 11, 2026 | $13.69 | $14.02 | $12.94 | $13.17 | 481.19K |
| Sep 10, 2026 | $13.88 | $14.02 | $13.395 | $13.49 | 566.24K |
| Sep 9, 2026 | $14.44 | $14.50 | $14.085 | $14.18 | 493.8K |
| Sep 8, 2026 | $14.57 | $15.29 | $14.1326 | $14.63 | 542.04K |
The latest Smart Investors Daily articles mentioning FDMT.
Company
Market Activity
Research & News
FDMT research
Company profile and research snapshot.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 29, 2026 | B of A Securities | Buy | — |
| Sep 14, 2026 | Cantor Fitzgerald | Overweight | — |
| Jul 31, 2026 | B. Riley Securities | Buy | — |
| Jul 20, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 20, 2026 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 29, 2026
Investing.com -- B. Riley Securities reiterated its Buy rating and $37 price target on 4D Molecular Therapeutics, citing the launch of a Phase 3 trial in diabetic macular edema and encouraging two-year data for its lead gene therapy candidate.
SeekingAlpha · Sep 29, 2026
4D Molecular Therapeutics remains a Buy as 4D-150 enters phase 3 for wet AMD/DME, cutting injections up to 87%. Click for more on FDMT stock.
Benzinga · Sep 29, 2026
B of A Securities analyst Tazeen Ahmad maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and raises the price target from $29 to $33.
Yahoo · Sep 28, 2026
OCUL’s selloff on Monday was spurred by clinical updates from competitors on their wet AMD treatments.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning FDMT.
